Skip to main content
Subscribe
Register
Sign in
Membership
Events
Knowledge Center
About
Subscribe
Register
Sign in
Premium
Alternative Insight and Premium Journalism
Latest Articles
Greenlight Gets Off to a Good Start in the Fourth Quarter
Steve Taub
November 4, 2024
Biopharma IPOs Have Surged. Will Tech Follow?
Steve Taub
October 31, 2024
Hedgies Brace for Magnificent Seven Earnings Reports
Steve Taub
October 30, 2024
Former Citadel Equity Pros Run Fund That Has Been Profitable Every Quarter Since Its Start
Steve Taub
October 29, 2024
Bears Bemoan Tesla Surge
Steve Taub
October 28, 2024
Why These Tiger Funds Continue to Outpace the Market
Steve Taub
October 24, 2024
Janus Henderson Maintains Its Wide Lead in Biotech
Steve Taub
October 23, 2024
Lone Pine Makes Back Earlier Losses
Steve Taub
October 22, 2024
Loeb Bullish on a Republican Win
Stephen Taub
October 21, 2024
Top Performing Averill Partners Closes to New Investors
Steve Taub
October 17, 2024
Einhorn: “We Are Likely to Underperform”
Steve Taub
October 16, 2024
D1 Capital’s Dan Sundheim Makes Changes After Two Consecutive Knockdowns
Steve Taub
October 15, 2024
Carvana Continues to Power Concentrated Fund Sosin
Steve Taub
October 14, 2024
Quantedge Leads Rebound in CTAs and Trend Following Hedge Funds
Steve Taub
October 10, 2024
Tech-Focused Cadian Suffers Another Loss, Adding to Its Woes This Year
Steve Taub
October 9, 2024
As Demand Grows for Evergreen Funds, Credit Manager Canyon Launches Its Own Version
Steve Taub
October 8, 2024
A Strong September Doesn’t Help Third Point’s Lagging Performance This Year
Steve Taub
October 7, 2024
Hedge Funds Slow Down on Life Science Deals
Steve Taub
October 3, 2024
More Articles